NRXP

NRXP

USD

NRX Pharmaceuticals Inc. Common Stock

$2.450-0.220 (-8.240%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$2.670

Kõrge

$2.700

Madal

$2.440

Maht

0.08M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

58.2M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

0.49M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $1.12Praegune $2.450Kõrge $6.01

Seotud uudised

Analyst Upgrades

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals with a Buy and maintains $34 price target.

Vaata rohkem
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
GlobeNewswire

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using an FDA-cleared device.HOPE is one of the first Ampa deployments nationwide and is now

Vaata rohkem
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
Analyst Upgrades

Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $47

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals with a Buy and raises the price target from $46 to $47.

Vaata rohkem
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $47
Analyst Upgrades

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals with a Buy and maintains $34 price target.

Vaata rohkem
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target